Diagnosis of such problems before the baby is born, allowing for prompt treatment within a week after birth, is known to markedly improve the prognosis, so there have been many attempts to develop technology to enables accurate and rapid diagnosis. However, today, fetal diagnosis depends heavily on observations by experienced examiners using ultrasound imaging, so it is unfortunately not uncommon for children to be born without having been properly diagnosed. In recent years, machine learning techniques such as deep learning have been developing rapidly, and there is great interest in the adoption of machine learning for medical applications. Machine learning can allow diagnostic systems to detect diseases more rapidly and accurately than human beings, but this requires the availability of adequate datasets on normal and abnormal subjects for a certain disease. Unfortunately, however, since congenital heart problems in children are relatively rare, there are no complete datasets, and up until now, prediction based on machine learning was not accurate enough for practical use in the clinic.

The goal of personalized decision making is to map a unit's characteristics to an action tailored to maximize the expected outcome for that unit. Obtaining high-quality mappings of this type is the goal of the dynamic regime literature. In healthcare settings, optimizing policies with respect to a particular causal pathway may be of interest as well. For example, we may wish to maximize the chemical effect of a drug given data from an observational study where the chemical effect of the drug on the outcome is entangled with the indirect effect mediated by differential adherence. In such cases, we may wish to optimize the direct effect of a drug, while keeping the indirect effect to that of some reference treatment. [16] shows how to combine mediation analysis and dynamic treatment regime ideas to defines policies associated with causal pathways and counterfactual responses to these policies. In this paper, we derive a variety of methods for learning high quality policies of this type from data, in a causal model corresponding to a longitudinal setting of practical importance. We illustrate our methods via a dataset of HIV patients undergoing therapy, gathered in the Nigerian PEPFAR program.

Although nonstationary data are more common in the real world, most existing causal discovery methods do not take nonstationarity into consideration. In this letter, we propose a kernel embedding-based approach, ENCI, for nonstationary causal model inference where data are collected from multiple domains with varying distributions. In ENCI, we transform the complicated relation of a cause-effect pair into a linear model of variables of which observations correspond to the kernel embeddings of the cause-and-effect distributions in different domains. In this way, we are able to estimate the causal direction by exploiting the causal asymmetry of the transformed linear model. Furthermore, we extend ENCI to causal graph discovery for multiple variables by transforming the relations among them into a linear nongaussian acyclic model. We show that by exploiting the nonstationarity of distributions, both cause-effect pairs and two kinds of causal graphs are identifiable under mild conditions. Experiments on synthetic and real-world data are conducted to justify the efficacy of ENCI over major existing methods.

Industrial robots play an important role in manufacturing process. Since robots are usually set up in parallel-serial settings, breakdown of a single robot has a negative effect on the entire manufacturing process in that it slows down the process. Therefore, fault diagnostic systems based on the internal signals of robots have gained a lot of attention as essential components of the services provided for industrial robots. The current work in fault diagnostic algorithms extract features from the internal signals of the robot while the robot is healthy in order to build a model representing the normal robot behavior. During the test, the extracted features are compared to the normal behavior for detecting any deviation. The main challenge with the existing fault diagnostic algorithms is that when the task of the robot changes, the extracted features differ from those of the normal behavior. As a result, the algorithm raises false alarm. To eliminate the false alarm, fault diagnostic algorithms require the model to be retrained with normal data of the new task. In this paper, domain adaptation, {\it a.k.a} transfer learning, is used to transfer the knowledge of the trained model from one task to another in order to prevent the need for retraining and to eliminate the false alarm. The results of the proposed algorithm on real dataset show the ability of the domain adaptation in distinguishing the operation change from the mechanical condition change.

In 2018, FireEye – a company based in California – informed Facebook and Google about a large group of fake Iranian social media accounts that was running movements to control the U.S people. As a result, Facebook and Google identified them, along with fake YouTube channels and blogs, using back-end data and then removed them. "Right now, you know something's automated just by the sheer volume of content pushing out," Lee Foster, information operations manager at FireEye, says. "It's not possible for a human to do this, so it's clearly not organically created. Often you'll see automated retweeting of some list of accounts that just to boost out a message. But the situation is about to take a new turn, he claims, as Artificial Intelligence (AI) system that covers its automated heritage is available now. "Imagine having a capability out there that can automate the organic creation of original content effectively enough that it looks real, but you don't even have to have it operate or touch it," Foster says. "In the very near term, the evolution of AI and machine learning, combined with the increasing availability of big data, will begin to transform human communication and interaction in the digital space.

The first artificial intelligence (AI) diagnostic system to gain clearance from the U.S. Food and Drug Administration beat out all predetermined benchmarks, achieving "high diagnostic accuracy" for patients with certain forms of diabetic retinopathy, according to clinical trial findings. IDx, the developer of the system, IDx-DR, published its results this week in the peer-reviewed journal Nature Digital Medicine. The paper provides an inside look into a technology that could transform how the industry diagnoses diabetic retinopathy, a condition that can cause blindness, bringing the process from the specialist's office to primary care -- without the need for a clinician to interpret the results. READ: First-of-Its-Kind AI Tool for Diabetic Retinopathy Detection Approved by FDA "This is formerly uncharted territory in healthcare, making it especially critical that we ensure the highest level of safety before introducing autonomous AI into patient care," Michael D. Abràmoff, M.D., Ph.D., IDx's founder and president and the study's principal investigator, said in a statement. In April, the FDA cleared IDx-DR, which analyzes images of the eye, for detection of "more than mild" diabetic retinopathy in adults with diabetes.

Nasa is working to contain a small leak onboard the International Space Station. The issue appears to be contained and the people on board the station do not appear to be under any immediate threat. But it did trigger a real alarm through the floating lab, which sent astronauts scrambling to find the cause of the problem. The crew was forced to check for the source of the leak by closing separate modules on the space station and finding which of them may be damaged. It was eventually tracked down in part of the Soyuz MS-09 spacecraft, which arrived at the station in early June carrying a crew of astronauts.

The first FDA-approved AI system for diagnosing eye diseases caused by diabetes is completely autonomous, and doesn't require a doctor to interpret the results. Several corporations including Google and DeepMind have been working on building algorithms for diabetic retinography, a leading cause of blindness amongst adults. The first biz to release a device approved by the US Food and Drug Administration (FDA) earlier this year in April, however, is less well-known. IDx LLC, an AI diagnostics company based in Iowa, developed the tool known as IDx-DR. The details about the system were published in a paper in Nature Digital Medicine on Tuesday.

A team of researchers at the Medical University of Vienna has recently evaluated the effectiveness of machine learning strategies to identify bacteraemia in patients affected by systemic inflammatory response syndrome (SIRS). Their study, published in Scientific Reports, gathered discouraging results, as machine learning methods could not achieve better accuracy than current diagnostic techniques. Bacteraemia is a frequent medical condition characterized by the presence of bacteria in the blood, with a mortality rate ranging between 13 percent and 21 percent. Past research suggests that a number of factors are associated with the risk of developing this condition, including advanced age, urinary or indwelling vascular catheter, chemotherapy, and immunosuppressive therapies. Diagnosing bacteraemia early is of crucial importance for the survival of affected patients, as they require prompt treatment with appropriate antibiotics.

Engineers at the center have taught a computer how to detect tiny specks of lung cancer in CT scans, which radiologists often have a difficult time identifying. The artificial intelligence system is about 95 percent accurate, compared to 65 percent when done by human eyes, the team said. "We used the brain as a model to create our system," said Rodney LaLonde, a doctoral candidate and captain of UCF's hockey team. "You know how connections between neurons in the brain strengthen during development and learn? We used that blueprint, if you will, to help our system understand how to look for patterns in the CT scans and teach itself how to find these tiny tumors."